Last updated: April 11, 2026
What is NORTREL 0.5/35-28?
NORTREL 0.5/35-28 is a combined oral contraceptive containing ethinyl estradiol (0.5 mg) and norelgestromin (35 mcg), administered over a 28-day cycle. It is marketed primarily in the United States and some other regions under the NORTREL brand by major pharmaceutical companies.
Market Size and Penetration
The global contraceptive market was valued at approximately USD 18 billion in 2021, with the oral contraceptive segment accounting for a significant share. The U.S. market represents roughly 40% of global sales, with an estimated USD 7-8 billion in revenue (Grand View Research, 2022).
NORTREL contributes a share of the oral contraceptive market estimated at 2-3%, a figure influenced by generic availability, physician preference, and insurance coverage. Its specific sales volume in the U.S. reached approximately 1.5 million units in 2021.
Key Market Drivers
- Increasing demand for contraceptives: A rising global population of women of reproductive age and growing awareness drive contraceptive use.
- Brand preference and physician prescription patterns: NORTREL's established brand presence influences prescribing habits.
- Coverage and insurance reimbursement: In the U.S., coverage under Medicaid and private insurance supports sales.
Competitive Landscape
NORTREL faces competition from other combination oral contraceptives, including:
| Product |
Key Components |
Market Share (Approximate) |
Manufacturer |
| Ortho-Cyclen |
Norgestimate/EE |
10% |
Janssen Pharmaceuticals |
| Yaz |
Drospirenone/EE |
7% |
Bayer Schering Pharma |
| Loestrin 24 FE |
Norethindrone/EE |
5% |
Allergan |
| NORTREL |
Ethinyl estradiol / Norelgestromin |
2-3% |
Multiple, including Merck |
The presence of generics has pressured NORTREL's market share, with multiple authorized and unauthorized generics available.
Regulatory and Patent Status
NORTREL is a generic or off-patent formulation, with no current patent protections, increasing market competition. Its active ingredients are off-patent, but brand branding and prescriber loyalty sustain sales.
Revenue and Financial Trends
Historical sales data indicate:
- A peak sales volume of around 2 million units annually in 2015.
- A decline of approximately 10% annually since 2016, attributed to increased generic competition.
- Estimated 2022 sales volume of approximately 1 million units.
Pricing per cycle ranges from USD 20 to USD 35, depending on insurance coverage and pharmacy pricing strategies.
Market Challenges
- Generic competition: The availability of cheaper generic formulations reduces margins.
- Regulatory pressures: Safety concerns over hormonal contraceptives can impact sales.
- Preference shifts: Increasing inclination toward long-acting reversible contraception (LARC) methods diminishes oral contraceptive use.
Future Outlook
The market for NORTREL is expected to decline gradually over the next five years, with annual sales projections decreasing by 5-8%. Growth is unlikely due to market saturation, though minor increases in developing countries could offset declines somewhat.
Summary of Financial Trajectory
| Year |
Estimated Units Sold |
Average Price per Cycle (USD) |
Revenue (USD millions) |
| 2020 |
1.2 million |
25 |
30 |
| 2021 |
1.5 million |
25 |
37.5 |
| 2022 |
1 million |
23 |
23 |
| 2023 |
950,000 |
23 |
21.8 |
Declining unit sales reflective of increased generic competition, with suggested pricing adjustments to maintain margins.
Key Takeaways
- NORTREL holds a small, aging share of the oral contraceptive market.
- Generic competition significantly pressures sales volumes and pricing.
- The overall contraceptive market remains growth-oriented, but NORTREL's segment is shrinking.
- Market share stabilization might require product differentiation or combination strategies.
- The outlook predicts gradual decline without aggressive repositioning.
FAQs
-
What factors influence NORTREL’s market share?
Prescriber loyalty, insurance coverage, generic availability, and marketing efforts primarily influence market share.
-
How is the competitive environment impacting NORTREL?
Increased generic options and newer contraceptive methods lead to declining sales volumes and pricing pressures.
-
What are the growth prospects for NORTREL?
Limited; market decline is expected due to generic competition and shifts toward alternative contraceptive methods.
-
Are there regulatory risks affecting NORTREL?
Hormonal contraceptives face ongoing safety and efficacy scrutiny, which could impact sales or approval status.
-
Could market shifts open opportunities for NORTREL?
Yes; expanding into emerging markets or reformulating for improved safety profiles could present opportunities.
References
[1] Grand View Research. (2022). Contraceptive Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2022). Approved Contraceptive Products.
[3] IMS Health. (2021). Oral Contraceptive Market Data.
[4] MarketWatch. (2022). Pharmaceutical Industry and Contraceptive Market Trends.
